Pharvaris N.V. ( (PHVS) ) has released its Q2 earnings. Here is a breakdown of the information Pharvaris N.V. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Pharvaris N.V. is a late-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists to address unmet needs in bradykinin-mediated diseases like hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH).
In its latest earnings report, Pharvaris highlighted significant progress in its clinical development programs, particularly with its lead candidate, deucrictibant. The company is on track with multiple Phase 3 studies and has successfully extended its financial runway through a substantial public offering.
Key financial metrics from the second quarter of 2025 include cash and cash equivalents of €200 million, with a subsequent $201 million public offering extending the cash runway into the first half of 2027. Research and development expenses increased to €29.6 million, while general and administrative expenses slightly decreased to €10.8 million. The company reported a net loss of €45.5 million for the quarter.
Pharvaris is advancing its clinical pipeline with ongoing and upcoming Phase 3 studies, including RAPIDe-3 and CHAPTER-3 for HAE treatment, and the initiation of the CREAATE study for AAE-C1INH by the end of 2025. These developments are expected to provide pivotal data in the coming years, potentially leading to new treatment options for patients.
Looking ahead, Pharvaris remains focused on executing its clinical programs and maintaining financial discipline. The company anticipates key data readouts that could significantly impact its strategic direction and market presence in the treatment of bradykinin-mediated angioedema.